| Followers | 71 |
| Posts | 9117 |
| Boards Moderated | 0 |
| Alias Born | 03/06/2016 |
Monday, May 25, 2026 8:26:17 PM
Hunt, What?
I believe we will hear of the MHRA decision the week of June 1st…most likely by Thursday June 4th…
If it goes beyond that date, then I believe we are owed an explanation as to what is behind the delay…
Investors have been very patient and trustworthy during the last 2 1/2 years since submission and if approval isn’t given by end of next week, then we should hear of the reason(s) why. Hiding behind “No announcement until decision” is reasonable for the first 18 months. However, we are beyond the point of a normal process. I assure you LP and Co. also strongly believed we would have learned of a decision within 18 months. So what gives?….I do not believe it is all MHRA delays. There is something else lurking in the dark. Regardless, it is time stakeholders are provided an update. How difficult can that be? I never expected a perfect submission and I can be understanding/forgiving, however I do expect a honest update.
As an example, if delays were caused by consultants not knowing 100% of the process for this paradigm shift and thus required us to provide additional data, etc. then any reasonable person could make an assumption that the delay would add at least 6 months+ to the approval process. Or perhaps the “assumed" extraordinary delay is due to the MHRA requiring submissions to the CHM four times vs. max of 2 for drugs. This new paradigm for GBM (and all cancer) treatments requires many new and different reviews not originally anticipated. Be assured, we have and continue to move forward meeting all the demands required. Though we don’t know the exact date when a decision will be rendered, we believe we are on a path closer to the end of the journey and looking forward to sharing such decision as soon as we hear. Please be patient with us as we near the goal line.
I believe we will hear of the MHRA decision the week of June 1st…most likely by Thursday June 4th…
If it goes beyond that date, then I believe we are owed an explanation as to what is behind the delay…
Investors have been very patient and trustworthy during the last 2 1/2 years since submission and if approval isn’t given by end of next week, then we should hear of the reason(s) why. Hiding behind “No announcement until decision” is reasonable for the first 18 months. However, we are beyond the point of a normal process. I assure you LP and Co. also strongly believed we would have learned of a decision within 18 months. So what gives?….I do not believe it is all MHRA delays. There is something else lurking in the dark. Regardless, it is time stakeholders are provided an update. How difficult can that be? I never expected a perfect submission and I can be understanding/forgiving, however I do expect a honest update.
As an example, if delays were caused by consultants not knowing 100% of the process for this paradigm shift and thus required us to provide additional data, etc. then any reasonable person could make an assumption that the delay would add at least 6 months+ to the approval process. Or perhaps the “assumed" extraordinary delay is due to the MHRA requiring submissions to the CHM four times vs. max of 2 for drugs. This new paradigm for GBM (and all cancer) treatments requires many new and different reviews not originally anticipated. Be assured, we have and continue to move forward meeting all the demands required. Though we don’t know the exact date when a decision will be rendered, we believe we are on a path closer to the end of the journey and looking forward to sharing such decision as soon as we hear. Please be patient with us as we near the goal line.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
